Jason Butler
Stock Analyst at JMP Securities
(2.27)
# 2,616
Out of 4,876 analysts
144
Total ratings
37.06%
Success rate
-0.91%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $22.45 | +64.81% | 14 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $12.36 | +215.53% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.45 | +315.22% | 10 | Jun 12, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $78 → $29 | $6.26 | +363.26% | 10 | May 27, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Market Perform | n/a | $7.95 | - | 5 | May 22, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $69.97 | +42.92% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $14.54 | +161.44% | 8 | May 7, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $7.26 | +354.55% | 3 | Apr 30, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $33.89 | +130.16% | 16 | Apr 10, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Market Outperform | $28 | $11.95 | +134.31% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $9.15 | +96.72% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.03 | +290.24% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $561.76 | +24.79% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.00 | +230.17% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $4.22 | +113.27% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $52.52 | +38.99% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.22 | +179.50% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.31 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.25 | +1,740.00% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $12.77 | +48.84% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $0.75 | +2,827.87% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.77 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $9.73 | +431,554.68% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $7.51 | +1,444.85% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.16 | +184.81% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.34 | - | 1 | Dec 2, 2020 |
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $22.45
Upside: +64.81%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $12.36
Upside: +215.53%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.45
Upside: +315.22%
Prothena Corporation
May 27, 2025
Maintains: Market Outperform
Price Target: $78 → $29
Current: $6.26
Upside: +363.26%
Vigil Neuroscience
May 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $7.95
Upside: -
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $69.97
Upside: +42.92%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $14.54
Upside: +161.44%
ABIVAX Société Anonyme
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $7.26
Upside: +354.55%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $33.89
Upside: +130.16%
Rapport Therapeutics
Apr 8, 2025
Initiates: Market Outperform
Price Target: $28
Current: $11.95
Upside: +134.31%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $9.15
Upside: +96.72%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.03
Upside: +290.24%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $561.76
Upside: +24.79%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.00
Upside: +230.17%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $4.22
Upside: +113.27%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $52.52
Upside: +38.99%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.22
Upside: +179.50%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.25
Upside: +1,740.00%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $12.77
Upside: +48.84%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $0.75
Upside: +2,827.87%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.77
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $9.73
Upside: +431,554.68%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $7.51
Upside: +1,444.85%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.16
Upside: +184.81%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.34
Upside: -